Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Balovaptan PK in Healthy Volunteers
NCT03586726Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balovaptan in Autism Spectrum Disorder (ASD), sponsored by Roche. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration Curve From Time 0 to 24 Hours. Started Jul 2018; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03586726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586726.